Paolo Zola, MD, Università degli Studi di Torino, Turin, Italy, provides the reasoning behind his randomized control trial (RTC) to evaluate the efficacy of minimalist versus intensive follow-up in patients treated for gynecological cancers. Whilst old papers on breast and ovarian cancers suggest there may not be an advantage associated with intensive management of patients, there is not enough solid data on this matter; Prof. Zola has designed an RCT where patients are monitored for resurgence by systematic CT scans, pap smears and biomarkers or simply by suspect symptoms to compare the efficacy of these approaches in detecting cancer reoccurrence. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
